Engineered Immune Cells Target Refractory Myeloma, Broader Cancer Potential
Steady progress towards engineering immune cells in the body now for refractory myeloma , with major implications for many autoimmune diseases and cancers https://t.co/K3IksrCFlg https://t.co/1AQ5rLuH1g
CEO Amy Burroughs Discusses M&A Post‑ASH25 Data
I asked $TERN CEO Amy Burroughs right after the #ASH25 data was out how she felt about M&A. Congrats to her and her team. https://t.co/2HemPoiqWO
Thousands of P-Values, only a Handful Are Real
1/ You ran 20,000 differential expression tests. 1,000 genes came back with p < 0.05. How many are real? Maybe 50. Maybe fewer. Most bioinformaticians learn p-values in stats class. Almost nobody learns why they break at scale. Let me explain: https://t.co/btC71ABX5N
MRK Likely to Rerun TERN Study for Data
Based on previous form $MRK will probably now rerun the $TERN study, just to prove to itself that the data were real.
TERN's Termination Terms Hint MRK Could Be Outbid
For those wondering if $MRK might be outbid, here are the deal termination terms from $TERN https://t.co/TbM3rWyEoG
Merck Spends $6.7B on CML Drug Despite Gleevec Era
It's amazing that 25 years after Gleevec we are still watching drug companies pay billions for new drugs for CML. And that, in Adam's previous story, a once deadly cancer was referred to as a chronic disease. Anyway, $MRK buys $TERN...
Amy Burrough
Adding $TERN to this list (Merck $6.7B reported) led by Amy Burroughs. Congrats to Amy and team 💪 https://t.co/KZ8CtA2GA0?
AVXL Withdraws Alzheimer's Drug From EMA After Rejection
$AVXL pulled its blarcamesine Alzheimer's application from the EMA after regulators there said there was no fking way it was going to approve a drug that does not work.
Novo
$NVO triple G drug at 2.16 A1c reduction at only week 24 vs a lower 1.9 A1c reduction at a longer 40 weeks for the max dose of the $LLY triple G. But Novo has no pipeline…? 🤷🏻♂️ https://t.co/CFcnGZGMqt
Hybrid PandaOmics‑Lobster Platform Accelerates Disease Target Discovery
PandaOmics and Lobster hybrid for novel target discovery and disease hypothesis research. @steipete will have serious impact on human life
CRBIOTECH's 2025 Impact Projected to Surge Significantly
📈 The projected 2025 impact of Current Research in Biotechnology is notably higher 🔗https://t.co/HTlbLhpaRc 🌐 #CRBIOTECH #Research #Science https://t.co/DOBMVCJUgC
D+Q Senolytic Linked to Brain Demyelination, Prompting Safety Concerns
The recent study showing D+Q causes demyelination in brain cells leads to more questions than it answers: (I only read the abstract cause paper new & paywalled.) D+Q has been used a lot in mice & humans. Why hasn't this been noticed...
Lyme Disease Isn’t a Bioweapon, Says Immunology Researcher
Since Lyme Disease is suddenly getting more attention than usual: Hi! I’m a researcher and scientist getting my PhD in Immunology, Infection and Epidemiology. I’ve been studying tick feeding and Lyme Disease for over 5 years now looking for an anti-tick...
Seeking Enzymes that Decolorize Anthocyanins Like Carotenoid Cleavers
Are there enzymes that cleave anthocyanins into colorless bits? I know there are carotenoid cleavage enzymes that can bite various parts of the saturated chain, but never heard of anthocyaninases... https://t.co/rUHXDWkWvc
Patience Wins: Wait for Maintenance Data, Not Hype
$ABVX degen traders dumping the stock on a CNBC article saying exactly what I’ve been saying since the trial hit back in July, and what was already blatantly obvious from the earnings release yesterday. WAITING FOR MAINTENANCE DATA is...
SWIFT-Seq Maps Single-Cell Transcriptomes of Myeloma CTCs
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of CTCs in multiple myeloma & precursors [Aug 8, 2025] Lightbody, @RomanosSP et al. @IrenemGhobrial - @LabGhobrial @NatureCancer https://t.co/LhqmRShFo9 #mmsm #LiquidBiopsy #cactc THREAD: https://t.co/87VZtDNy80 https://t.co/41MRROCXwI
Sex‑specific Epigenetic Network Drives Cholesterol and Atherosclerosis
Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprograming of hepatocytes https://t.co/2XpUt6ndcs https://t.co/r5DvCeGMeS
Focus on Fundamentals, Not Every New Sequencing Method
1/ I used to panic every time a new *Seq method dropped. ATAC-seq, CUT&Tag, scNOMe-seq, SHARE-seq... the list never ends. I tried to learn them all. I burned out. Here's what I wish someone told me earlier. https://t.co/xUlsvXmaQh
New AD Combos Outpace Dupilumab, Injection Frequency Drops
Atopic dermatitis landscape from Wedbush. Looks like there are two parallel vectors: lower injection frequency ( $APGE ) and combining new mechanisms with IL13/IL4R. So far $JNJ's IL13+IL31 failed (the only one to be directly compared to dupi) while $PFE's...
Patented Chemo Reform Boosted Profits, Not Patient Benefits
Please. This is nonsense. You figured out a way to swap castor oil for albumin making it easier to administer paclitaxel, a standard chemotherapy. Same side effects. Look at the label. The best thing you did, for you, was secure...
Aging May Be Reversible by Restoring Cellular Information
It’s not often that a theory about aging feels this transformative. I recently came across research suggesting that aging may not be permanent damage — but a loss of biological information inside our cells. Think of it like a scratched CD. The data...
AI-Driven Partnership Targets Unmet Gynecological Diseases
We are very happy to join forces together with the wonderful ASKA to go after Novel Targets for Women's Health. Gynecological diseases have long posed challenges, including difficult diagnosis, limited treatment options, and a substantial disease burden, affecting millions of...
P‑tau217 Predicts Dementia Risk with Combined Hormone Therapy
Blood levels of the Alzheimer's biomarker p-tau217 may help identify which women are more vulnerable to dementia when using combined hormone therapy after menopause, while estrogen-only therapy does not show the same association. menopause
Direct Immune Cell Injection Eradicates Multiple Mouse Cancers
A potentially game-changing discovery by @UCSF's Justin Eyquem @j_eyquem & colleagues – injecting cancer-fighting immune cells directly into the body kills several types of cancers in mice. Paper in @Nature: https://t.co/EXbsfx7whl Summary/video by UCSF: https://t.co/qLYXXvEDTV
Doctors Endorse Peptides as Effective and Favorable
Meanwhile: Anecdotal data: "I spoke lots of doctors, they all said peptides are great and they like them"
Keyboard Shortcuts Let You Reposition Plasmid Origins Instantly
I love this so much lololol You can use the arrow keys to circularly permute the plasmid to shift the reference origin as you please, you can use . and , to adjust the circularity of the...
Vibecoding Peaks Between PCRs, Meeting at 9
Vibecoding between PCR's has hit an all time high. See you at 9pm, Claude. https://t.co/8mJv5GJIut
ABVX Hires Entyvio Creator, Silencing CCO Doubts
$ABVX panicans were worried about a CCO hire and the company just went out & got the dude who launched Entyvio. Let's go! 🔥🔥🔥
Brief 5‑MeO‑DMT Trip Yields Month‑Long Antidepressant Boost
One of the most remarkable things about 5-meo-DMT as an antidepressant is that the psychoactive experience is so brief. 10 minute peak, perhaps. 20 min total. And people seldom remember it well. Yet it has possibly the largest anti-depressant effect...
Cyborg Organoids Sense Glucose, Release Hormones for Diabetes
Bioengineers embedded soft, stretchable electronics into the tiny clusters to create “cyborg” organoids. These can mimic the pancreas, sensing glucose levels and releasing hormones. They could help build replacement cells for people with type 1 diabetes. https://spectrum.ieee.org/cyborg-stem-cell-therapy-for-diabetes
AI and Genomics Target Aging to Combat Chronic Disease
Aging underpins most chronic diseases and remains the biggest challenge to human health. Thank you @carninci for the opportunity to present @humantechnopole on aging, genomics and AI approaches to identify longevity targets and drugs. https://t.co/ysDGHfJeY0
Fermented Cordyceps Broth Improves Primary Insomnia in Trial
Effectiveness of fermentation broth of Cordyceps sinensis for primary insomnia: a randomized clinical trial with digital health tool https://t.co/g5iOuzkctO
Reagent Spend Under 5%—Biotech Must Address Cost Gap
The thing to look at in biotech is your reagent costs as a % of your total research spending - inclusive of lab space, EHS, equipment maintenance, lab labor costs, etc. Lab data is the concrete output of biotech...
Consumer Longevity Research Gains Momentum with Ginkgo Cloud Lab
Really excited about the use of @Ginkgo Cloud Lab for consumers to do research in longevity and other consumer apps. These areas are less well-studied than you'd expect as US research funding is largely oriented towards disease. Fun chatting with @LongevityTech about...
US Patients Access Zegfrovy via Apex Oncology
Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> https://t.co/4GVjyHS9vz https://t.co/bjjrnZkNL6
Pfizer's Lyme Vaccine Data Remains Ambiguous, FDA Review Looms
As someone who lived in Vermont and still spends the summer there, it's disappointing to see the ambiguity in Pfizer's data on a new Lyme disease vaccine. It's a serious threat. Now we can move on to speculating on the...
Thymus Gland Emerges as Key to Healthy Aging
Don't take the time to read about the new landmark studies that put our thymus gland at center stage for healthy aging https://t.co/ENhIn2A2l3 https://t.co/oY2PLSenmf
FDA OKs Fecal Transplants, Yet Access Declines
Paradox: The FDA approved some fecal transplants for C. difficile. But accessing treatment got harder. https://t.co/AFFyCGPeKW
Phase 3 Lyme Vaccine Shows Mixed Preliminary Results
The news is mixed in the preliminary results from a Phase 3 trial of a needed #Lyme disease vaccine, @matthewherper reports. https://t.co/bcbfeXchk1
Real Bioinformatics Data Is Messy, Not Perfect
1/ Every bioinformatics tutorial is lying to you. They give you clean data, perfect sample names, and zero missing values. Then you open a real dataset and nothing works. Here's what they don't teach you.
Lyme Vaccine Hits 70% Efficacy, Misses Confidence Threshold
The $PFE/ $VALN Lyme vaccine was a product for which there was a lot of hope. Results today show OK efficacy. Vaccine efficacy landed at 70%; investors hoped for 80% but thought as low as 60% would be relevant. But the...
Portable DNA Tests Map Cave Microbes in Real Time
Field-portable genetic assays now enable rapid, on-site mapping of cave microbial ecosystems, offering near real-time insights into biodiversity and potential health threats without reliance on traditional lab methods. microbiology
CtDNA Drives Next‑stage Risk Stratification in TNBC
From Prognosis to Action: Circulating Tumor DNA and the Next Phase of Risk Stratification in Triple-Negative Breast Cancer [Mar 18, 2026] Schneider & @StoverLab @JCO_ASCO https://t.co/6jPBxQe9QP #bcsm #PrecisionMedicine #LiquidBiopsy https://t.co/MOG73iTcNl
New Guidelines Add Testing, Therapy for ESR1‑mutated Metastatic Breast Cancer
Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy https://t.co/KBx2hq2BDW
Low‑
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/3Pa2TRMntk
Personalized Therapy Improves Outcomes in Residual TNBC
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer [Dec 15, 2021] Schneider et al. Radovich @JCO_ASCO https://t.co/oJm6BJrMtA #bcsm #PrecisionMedicine
Genetic Links to Aromatase Inhibitor Musculoskeletal Side Effects
Genome-Wide Associations [GWAS] and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors [Sep 20, 2010] Ingle et al. @DrWeinshilboum @JCO_ASCO https://t.co/1NJcXkWy8c #bcsm #Supponc
Circulating DNA/Cells Predict Recurrence Post‑Chemo in TNBC
Assoc of Circulating Tumor DNA & Circulating Tumor Cells After Neoadjuvant Chemotherapy w/ Disease Recurrence in Pts w/ Triple-Negative Breast Cancer: BRE12-158 RCT [Jul 9, 2020] Radovich et al. @JAMAOnc https://t.co/XxH9kTT9d5 #bcsm #cactc #NCT02101385 https://t.co/kgV0yM2I1f
Pfizer's Lyme Phase 3 Cut by One‑Third Over Contractor Issues
Pfizer's phase 3 for its Lyme trial was supposed to be 18k patients -- but issues with a contractor at the start of the trial cut the size by a third, and @ky_lahucik + I reported a long time ago...
P7C3 Boosts NAD Enzyme, Improves Mouse Alzheimer Model
P7C3 is an activator of an enzyme that makes NAD called NAMPT. Cool that it’s working in a 🐁 model of AD 👏
